Skip to main content
PMC home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1996 Apr;50(2):190–195. doi: 10.1136/jech.50.2.190

Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden.

L Lindholm 1, M Rosén 1, L Weinehall 1, K Asplund 1
PMCID: PMC1060251  PMID: 8762387

Abstract

STUDY OBJECTIVE: To evaluate the cost effectiveness and equity of a community based cardiovascular disease prevention programme. DESIGN: A prospective cross sectional design. SETTING: A community based intervention to reduce cardiovascular disease in the district of Norsjö (n = 5500), Sweden. The intervention was aimed at both the general population and at individuals thought to be at special risk, the emphasis being on changing dietary habits and reducing cholesterol concentrations. PARTICIPANTS: The participants were men and women aged 30-60 years. MAIN RESULTS: The mean serum cholesterol concentration in the Norsjö population was reduced by nearly 20% during the first six years of intervention. It was estimated that the programme's overall total societal costs were 363,000 pounds and estimates of the cost per year of life saved ranged from 14,900 pounds to net savings, according to different assumptions. Taking only health care costs and savings into account, the cost per year of life saved ranged from 1100 pounds to 4050 pounds. The results varied between different sex and age groups, but not between social classes. Even if a causal relationship exists between low cholesterol concentrations and excess mortality, the estimated side effects of lowering cholesterol values in Norsjö were negligible in comparison with the expected benefits. CONCLUSIONS: The community based intervention in Norsjö seems to be cost effective even under conservative assumptions. The approach used seems to have benefited all social classes. Cost effectiveness analyses that take consequences for equity into account are valuable tools in decision making.

Full text

PDF
190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G., Flora J. A., Fortmann S. P., Farquhar J. W. The cost-effectiveness of three smoking cessation programs. Am J Public Health. 1987 Feb;77(2):162–165. doi: 10.2105/ajph.77.2.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brännström I., Rosén M., Wall S., Weinehall L. Local health planning and intervention--the case of a Swedish municipality. Scand J Prim Health Care Suppl. 1988;1:57–64. [PubMed] [Google Scholar]
  3. Brännström I., Weinehall L., Persson L. A., Wester P. O., Wall S. Changing social patterns of risk factors for cardiovascular disease in a Swedish community intervention programme. Int J Epidemiol. 1993 Dec;22(6):1026–1037. doi: 10.1093/ije/22.6.1026. [DOI] [PubMed] [Google Scholar]
  4. Chambless L. E., Dobson A. J., Patterson C. C., Raines B. On the use of a logistic risk score in predicting risk of coronary heart disease. Stat Med. 1990 Apr;9(4):385–396. doi: 10.1002/sim.4780090410. [DOI] [PubMed] [Google Scholar]
  5. Davey Smith G., Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992 Feb 15;304(6824):431–434. doi: 10.1136/bmj.304.6824.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gordon T., Kannel W. B. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J. 1982 Jun;103(6):1031–1039. doi: 10.1016/0002-8703(82)90567-1. [DOI] [PubMed] [Google Scholar]
  7. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990 Dec;82(6):1916–1924. doi: 10.1161/01.cir.82.6.1916. [DOI] [PubMed] [Google Scholar]
  8. Huhtasaari F., Asplund K., Wester P. O. Cardiovascular risk factors in the Northern Sweden MONICA Study. Acta Med Scand. 1988;224(2):99–108. doi: 10.1111/j.0954-6820.1988.tb16746.x. [DOI] [PubMed] [Google Scholar]
  9. Hulley S. B., Walsh J. M., Newman T. B. Health policy on blood cholesterol. Time to change directions. Circulation. 1992 Sep;86(3):1026–1029. doi: 10.1161/01.cir.86.3.1026. [DOI] [PubMed] [Google Scholar]
  10. Jacobs D., Blackburn H., Higgins M., Reed D., Iso H., McMillan G., Neaton J., Nelson J., Potter J., Rifkind B. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation. 1992 Sep;86(3):1046–1060. doi: 10.1161/01.cir.86.3.1046. [DOI] [PubMed] [Google Scholar]
  11. Kinlay S., O'Connell D., Evans D., Francis L. The validity of estimating heart disease reduction from a Framingham logistic equation. J Clin Epidemiol. 1992 May;45(5):553–560. doi: 10.1016/0895-4356(92)90105-v. [DOI] [PubMed] [Google Scholar]
  12. Kinosian B. P., Eisenberg J. M. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988 Apr 15;259(15):2249–2254. doi: 10.1001/jama.259.15.2249. [DOI] [PubMed] [Google Scholar]
  13. Kottke T. E., Puska P., Feldman R., Salonen J. T., Tuomilehto J. A decline in earning losses associated with a community-based cardiovascular disease prevention project. Med Care. 1982 Jul;20(7):663–675. doi: 10.1097/00005650-198207000-00002. [DOI] [PubMed] [Google Scholar]
  14. Kristiansen I. S., Eggen A. E., Thelle D. S. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? BMJ. 1991 May 11;302(6785):1119–1122. doi: 10.1136/bmj.302.6785.1119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Law M. R., Thompson S. G., Wald N. J. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994 Feb 5;308(6925):373–379. doi: 10.1136/bmj.308.6925.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Law M. R., Wald N. J., Wu T., Hackshaw A., Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994 Feb 5;308(6925):363–366. doi: 10.1136/bmj.308.6925.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Leaverton P. E., Sorlie P. D., Kleinman J. C., Dannenberg A. L., Ingster-Moore L., Kannel W. B., Cornoni-Huntley J. C. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis. 1987;40(8):775–784. doi: 10.1016/0021-9681(87)90129-9. [DOI] [PubMed] [Google Scholar]
  18. Lindholm L., Rosén M., Hellsten G. Are people willing to pay for a community-based preventive program. Int J Technol Assess Health Care. 1994 Spring;10(2):317–324. doi: 10.1017/s0266462300006280. [DOI] [PubMed] [Google Scholar]
  19. MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 Mar 31;335(8692):765–774. doi: 10.1016/0140-6736(90)90878-9. [DOI] [PubMed] [Google Scholar]
  20. Muldoon M. F., Manuck S. B., Matthews K. A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990 Aug 11;301(6747):309–314. doi: 10.1136/bmj.301.6747.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nissinen A., Tuomilehto J., Enlund H., Kottke T. E. Costs and benefits of community programmes for the control of hypertension. J Hum Hypertens. 1992 Dec;6(6):473–479. [PubMed] [Google Scholar]
  22. Nissinen A., Tuomilehto J., Kottke T. E., Puska P. Cost-effectiveness of the North Karelia Hypertension Program. 1972-1977. Med Care. 1986 Aug;24(8):767–780. doi: 10.1097/00005650-198608000-00012. [DOI] [PubMed] [Google Scholar]
  23. Olsson G., Levin L. A., Rehnqvist N. Economic consequences of postinfarction prophylaxis with beta blockers: cost effectiveness of metoprolol. Br Med J (Clin Res Ed) 1987 Feb 7;294(6568):339–342. doi: 10.1136/bmj.294.6568.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Phillips C. J., Prowle M. J. Economics of a reduction in smoking: case study from Heartbeat Wales. J Epidemiol Community Health. 1993 Jun;47(3):215–223. doi: 10.1136/jech.47.3.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ. 1992 Jul 4;305(6844):15–19. doi: 10.1136/bmj.305.6844.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Smith G. D., Shipley M. J., Marmot M. G., Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA. 1992 Jan 1;267(1):70–76. [PubMed] [Google Scholar]
  27. Svärdsudd K., Tibblin G. Mortality and morbidity during 13.5 years' follow-up in relation to blood pressure. The study of men born in 1913. Acta Med Scand. 1979;205(6):483–492. doi: 10.1111/j.0954-6820.1979.tb06089.x. [DOI] [PubMed] [Google Scholar]
  28. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A. M., Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994 Jul;90(1):583–612. doi: 10.1161/01.cir.90.1.583. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES